We are live on ! Find out more
CA

CHI Advisors Portfolio holdings

AUM $252M
1-Year Est. Return 56.99%
This Fund
S&P 500
This Quarter Est. Return
+31.2%
1 Year Est. Return
+56.99%
3 Year Est. Return
+88.23%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$256M
AUM Growth
+$214M
Cap. Flow
+$190M
Cap. Flow %
74.04%
Top 10 Hldgs %
96.91%
Holding
19
New
6
Increased
2
Reduced
9
Closed
–

Top Buys

Rank Stock Value
1
RPTX
Repare Therapeutics
RPTX
+$80.4M
2
PLRX icon
Pliant Therapeutics
PLRX
+$61.2M
3
AKUS
Akouos Inc
AKUS
+$21.7M
4
KROS icon
Keros Therapeutics
KROS
+$17.9M
5
LRMR icon
Larimar Therapeutics
LRMR
+$17.6M

Top Sells

Rank Stock Value
1
LVGO
Livongo Health, Inc. Common Stock
LVGO
+$3.93M
2
RARE icon
Ultragenyx Pharmaceutical
RARE
+$1.74M
3
BPMC
Blueprint Medicines
BPMC
+$1.62M
4
OVID icon
Ovid Therapeutics
OVID
+$1.33M
5
KZR
Kezar Life Sciences
KZR
+$595K

Sector Composition

Rank Sector Weight
1 Healthcare 99.56%
2 Communication Services 0.44%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RPTX
1
DELISTED
Repare Therapeutics
RPTX
$77.7M 30.3%
+2,503,408
New +$80.4M
PLRX icon
2
Pliant Therapeutics
PLRX
$71.2M
$74.9M 29.21%
+2,305,994
New +$61.2M
AKUS
3
DELISTED
Akouos Inc
AKUS
$21.9M 8.56%
+974,985
New +$21.7M
KROS icon
4
Keros Therapeutics
KROS
$223M
$21.7M 8.49%
+579,744
New +$17.9M
LRMR icon
5
Larimar Therapeutics
LRMR
$421M
$19.5M 7.6%
+1,515,148
New +$17.6M
ORTX
6
DELISTED
Orchard Therapeutics plc American Depositary Shares
ORTX
$17.6M 6.86%
293,119
-3,108
-1% -$285K
DTIL icon
7
Precision BioSciences
DTIL
$232M
$8M 3.12%
32,001
+649
+2% +$142K
OVID icon
8
Ovid Therapeutics
OVID
$572M
$4.01M 1.57%
544,281
-284,132
-34% -$1.33M
KZR
9
DELISTED
Kezar Life Sciences
KZR
$1.77M 0.69%
34,097
-11,792
-26% -$595K
MYOK
10
DELISTED
MyoKardia, Inc. Common Stock
MYOK
$1.3M 0.51%
13,500
-1,500
-10% -$125K
LVGO
11
DELISTED
Livongo Health, Inc. Common Stock
LVGO
$1.13M 0.44%
15,000
-75,000
-83% -$3.93M
GTHX
12
DELISTED
G1 Therapeutics, Inc. Common Stock
GTHX
$1.07M 0.42%
+44,000
New +$728K
ADVM
13
DELISTED
Adverum Biotechnologies
ADVM
$1.04M 0.41%
5,000
-1,375
-22% -$244K
RARE icon
14
Ultragenyx Pharmaceutical
RARE
$2.59B
$1.02M 0.4%
13,000
-26,362
-67% -$1.74M
CRVS icon
15
Corvus Pharmaceuticals
CRVS
$1.24B
$990K 0.39%
364,132
– –
BPMC
16
DELISTED
Blueprint Medicines
BPMC
$936K 0.37%
12,000
-24,000
-67% -$1.62M
GBT
17
DELISTED
Global Blood Therapeutics, Inc.
GBT
$821K 0.32%
13,000
-2,750
-17% -$189K
BLUE
18
DELISTED
bluebird bio
BLUE
$488K 0.19%
618
+155
+33% +$117K
COGT icon
19
Cogent Biosciences
COGT
$6.44B
$433K 0.17%
235,201
– –

Similar funds

SC
Samjo Capital New York $254M AUM 36.81% 1-Year Est. Return
T
TRUADVICE Sarasota, Florida $255M AUM 14.45% 1-Year Est. Return
W
WealthOne Albany, New York $248M AUM 17.79% 1-Year Est. Return
RBGI
Ribbit Bullfrog GP II Palo Alto, California $258M AUM 33.43% 1-Year Est. Return
TOGEPT
Trustees of General Electric Pension Trust Norwalk, Connecticut $245M AUM 128.88% 1-Year Est. Return
IAM
Innovis Asset Management Chicago, Illinois $260M AUM 28.13% 1-Year Est. Return
RCGI
Ribbit Capital GP II Palo Alto, California $260M AUM 2.87% 1-Year Est. Return
AEPLI
AH Equity Partners LSV III Menlo Park, California $262M AUM 59.24% 1-Year Est. Return

CHI Advisors's Q2 2020 Portfolio in Review

As of Q2 2020, CHI Advisors held 19 positions worth $256M, up 504% from $42.4M the previous quarter. Its ten largest holdings account for 97% of the portfolio.

CHI Advisors deployed $190M of net new capital in Q2 2020, opening 6 new positions and adding to 2 existing holdings. Its largest new stake was Repare Therapeutics: 2,503,408 shares worth $77.7M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 94% a quarter earlier, followed by Communication Services.

On the sell side, the largest reduction was Livongo Health, Inc. Common Stock, an estimated $3.93M trimmed.

  • CHI Advisors's largest Q2 2020 buy was Repare Therapeutics: 2,503,408 shares worth $77.7M.
  • CHI Advisors added most to Precision BioSciences in Q2 2020, an estimated $142K increase.
  • CHI Advisors's biggest Q2 2020 reduction was Livongo Health, Inc. Common Stock, cutting an estimated $3.93M.
  • CHI Advisors's ten largest holdings make up 97% of its $256M portfolio in Q2 2020.
  • CHI Advisors opened 6 new positions and closed 0 in Q2 2020.
  • CHI Advisors's portfolio value rose 504% quarter-over-quarter to $256M.

Based on CHI Advisors's 13F filing for Q2 2020, filed 12 Aug 2020.